Early research (Phase 1)Active Not RecruitingNCT05509790What this trial is testingLY3484356 in Chinese Participants With Advanced Breast CancerWho this might be right forBreast Neoplasms Eli Lilly and Company 17
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07173556What this trial is testingA Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast CancerWho this might be right forAdvanced Breast Cancer Qilu Pharmaceutical Co., Ltd. 96
Early research (Phase 1)Ended earlyNCT05489679What this trial is testingAC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Accutar Biotechnology Inc 6
Early research (Phase 1)Looking for participantsNCT05508906What this trial is testingPhase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerWho this might be right forMetastatic Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+2 more Olema Pharmaceuticals, Inc. 190
Large-scale testing (Phase 3)Study completedNCT03176238What this trial is testingStudy in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerWho this might be right forPost Menopausal Breast Cancer Novartis Pharmaceuticals 235
Testing effectiveness (Phase 2)Study completedNCT02954055What this trial is testingMEtronomic TrEatment Option in Advanced bReast cAncerWho this might be right forBreast Cancer ETOP IBCSG Partners Foundation 140
Testing effectiveness (Phase 2)Ended earlyNCT03584009What this trial is testingA Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor TherapyWho this might be right forEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer Hoffmann-La Roche 103
Large-scale testing (Phase 3)Ended earlyNCT02340221What this trial is testingTaselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor TherapyWho this might be right forBreast Cancer Hoffmann-La Roche 631
Testing effectiveness (Phase 2)Study completedNCT03250676What this trial is testingTrial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast CancerWho this might be right forBreast NeoplasmsBreast CancerEstrogen-receptor Positive Breast Cancer+5 more Eisai Inc. 151
Early research (Phase 1)Active Not RecruitingNCT05654532What this trial is testingStudy of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Accutar Biotechnology Inc 100
Testing effectiveness (Phase 2)UnknownNCT04669587What this trial is testingER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)Who this might be right forEstrogen Receptor-PositiveHER2-NegativeLocally Advanced Breast Cancer+1 more EnhancedBio USA Inc. 106
Early research (Phase 1)Study completedNCT02684032What this trial is testingAssess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast CancerWho this might be right forBreast Cancer Celcuity Inc 141
Large-scale testing (Phase 3)Active Not RecruitingNCT05306340What this trial is testingA Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Who this might be right forEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer Genentech, Inc. 373
Early research (Phase 1)Active Not RecruitingNCT04993430What this trial is testingHRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast CancerWho this might be right forER-Positive, HER2-Negative Breast Cancer Shanghai Hengrui Pharmaceutical Co., Ltd. 46
Testing effectiveness (Phase 2)Looking for participantsNCT07100106What this trial is testingEvaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerWho this might be right forBreast Cancer Genentech, Inc. 285
Testing effectiveness (Phase 2)Active Not RecruitingNCT02311933What this trial is testingTamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerWho this might be right forRecurrent Breast CarcinomaStage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7+3 more National Cancer Institute (NCI) 81
Testing effectiveness (Phase 2)Study completedNCT02732119What this trial is testingStudy of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.Who this might be right forBreast Cancer Novartis Pharmaceuticals 104
Large-scale testing (Phase 3)Ended earlyNCT01303679What this trial is testing1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast CancerWho this might be right forFirst Line Metastatic Breast Cancer ARCAGY/ GINECO GROUP 117
Large-scale testing (Phase 3)Looking for participantsNCT06954961What this trial is testingEvaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer InventisBio Co., Ltd 640
Early research (Phase 1)Study completedNCT01857193What this trial is testingPhase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast CancerWho this might be right forBreast Cancer Novartis Pharmaceuticals 132